Clinical Trial

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).
Protocol Amendment History 96 amendments
This ClinicalTrials.gov record has been amended 96 times since 2015-12-09; most recent amendment 2025-09-18.
Status change: Recruiting → Active, Not Recruiting 2025-07-21
Status change: Not Yet Recruiting → Recruiting 2016-01-04
Trial Details
NCT Number NCT02628067
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Advanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer, Cholangiocarcinoma, Bile Duct Cancer, Neuroendocrine Tumor, Carcinoid Tumor +17 more
Enrollment 1,609 participants
Start Date 2015-12-18
Primary Completion 2027-05-04 (estimated)
Study Completion 2027-05-04 (estimated)
Updated on ClinicalTrials.gov 2025-09-22